NewAmsterdam Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . NewAmsterdam Pharma
NAMSW Stock   25.97  2.79  12.04%   
NewAmsterdam Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing NewAmsterdam Pharma's valuation are provided below:
Gross Profit
22.5 M
Revenue
22.5 M
Quarterly Revenue Growth
(1.00)
Revenue Per Share
0.19
There are over one hundred nineteen available fundamental ratios for NewAmsterdam Pharma, which can be analyzed over time and compared to other ratios. All traders should should check NewAmsterdam Pharma's last-minute fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable.

NewAmsterdam Pharma Total Revenue

33.89 Million

Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 29 M or Interest Income of 29 M, as well as many indicators such as Price To Sales Ratio of 187, Dividend Yield of 0.0 or PTB Ratio of 6.17. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Build AI portfolio with NewAmsterdam Stock
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

NewAmsterdam Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets489 M769.3 M267.9 M
Slightly volatile
Short and Long Term Debt Total191.9 K202 K7.6 M
Slightly volatile
Other Current Liabilities40.5 M72.7 M15.4 M
Slightly volatile
Total Current Liabilities53.2 M85.8 M20.3 M
Slightly volatile
Total Stockholder Equity429.6 M683.4 M238.1 M
Slightly volatile
Property Plant And Equipment Net316.1 K568 K127.1 K
Slightly volatile
Accounts Payable9.1 M9 M3.6 M
Slightly volatile
Cash390.8 M490 M149.2 M
Slightly volatile
Non Current Assets Total98.3 M93.6 M100.8 M
Slightly volatile
Cash And Short Term Investments429.1 M636.2 M163.7 M
Slightly volatile
Common Stock Shares Outstanding63.3 M114.4 M34.5 M
Slightly volatile
Liabilities And Stockholders Equity489 M769.3 M267.9 M
Slightly volatile
Non Current Liabilities Total62.7 K66 K9.1 M
Slightly volatile
Other Current Assets8.4 M16.3 M3.5 M
Slightly volatile
Other Stockholder Equity1.5 B1.4 B291.8 M
Slightly volatile
Total Liabilities59.4 M85.9 M29.8 M
Slightly volatile
Net Invested Capital914.7 M871.1 M203.2 M
Slightly volatile
Property Plant And Equipment Gross812.6 K774 K172.2 K
Slightly volatile
Short and Long Term Debt9.3 M10.5 M11.4 M
Slightly volatile
Total Current Assets446 M675.7 M170.4 M
Slightly volatile
Capital Stock11.5 M12.1 M44.6 M
Pretty Stable
Short Term Debt129.2 K136 K7.6 M
Slightly volatile
Common Stock22.7 M14.3 M83.4 M
Slightly volatile
Current Deferred Revenue5.7 M4 M4.8 M
Slightly volatile
Net Receivables11.7 M23.2 M7 M
Slightly volatile
Accumulated Other Comprehensive Income4.1 M4.8 M1.8 M
Slightly volatile
Good Will186.5 K209.8 K229 K
Slightly volatile
Intangible Assets362.7 K407 K245.7 K
Slightly volatile
Other Assets22.4 K25.1 K27.4 K
Slightly volatile

NewAmsterdam Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization231 K220 K37.7 K
Slightly volatile
Selling General Administrative111.6 M106.3 M21.7 M
Slightly volatile
Selling And Marketing Expenses4.9 M4.7 M1.2 M
Slightly volatile
Other Operating Expenses149.4 M248.2 M60.6 M
Slightly volatile
Research Development105.1 M141.8 M42.8 M
Slightly volatile
Total Operating Expenses149.4 M248.1 M60.6 M
Slightly volatile
Reconciled Depreciation231 K220 K41.8 K
Slightly volatile
Cost Of Revenue66.4 K59 K31.1 K
Slightly volatile

NewAmsterdam Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow810.3 M771.7 M146.7 M
Slightly volatile
Depreciation231 K220 K37.7 K
Slightly volatile
Capital Expenditures220.5 K246 K93.1 K
Slightly volatile
Total Cash From Financing Activities28 M29.5 M79.7 M
Slightly volatile
End Period Cash Flow392.5 M491.3 M154.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio18717830.0067
Slightly volatile
PTB Ratio6.175.8722.2482
Slightly volatile
Days Sales Outstanding39437695.4517
Slightly volatile
Book Value Per Share9.275.97417.7431
Pretty Stable
Average Payables5.2 M8.5 M5 M
Slightly volatile
Stock Based Compensation To Revenue2.772.64080.4949
Slightly volatile
Capex To Depreciation1.061.118210.6516
Slightly volatile
PB Ratio6.175.8722.2482
Slightly volatile
Payables Turnover0.00530.00590.0065
Slightly volatile
Sales General And Administrative To Revenue4.964.72360.9629
Slightly volatile
Research And Ddevelopement To Revenue4.366.30282.1342
Slightly volatile
Capex To Revenue0.00590.01090.0036
Slightly volatile
Cash Per Share6.225.56163.1573
Slightly volatile
Days Payables Outstanding44.4 K49.9 K54.5 K
Slightly volatile
Intangibles To Total Assets4.0E-45.0E-45.0E-4
Slightly volatile
Net Debt To EBITDA1.922.02131.9831
Slightly volatile
Current Ratio9.177.87658.1294
Pretty Stable
Tangible Book Value Per Share9.265.97057.7413
Pretty Stable
Receivables Turnover0.920.9726.4059
Slightly volatile
Shareholders Equity Per Share9.275.97417.7431
Pretty Stable
Debt To Equity3.0E-43.0E-40.0024
Slightly volatile
Capex Per Share0.00310.00220.0021
Slightly volatile
Revenue Per Share0.190.19674.2018
Slightly volatile
Interest Debt Per Share0.00170.00180.0304
Slightly volatile
Debt To Assets2.0E-43.0E-40.002
Slightly volatile
Operating Cycle39437695.4517
Slightly volatile
Price Book Value Ratio6.175.8722.2482
Slightly volatile
Days Of Payables Outstanding44.4 K49.9 K54.5 K
Slightly volatile
Ebt Per Ebit0.860.90311.371
Pretty Stable
Company Equity Multiplier0.921.12561.1044
Very volatile
Long Term Debt To Capitalization1.0E-41.0E-41.0E-4
Slightly volatile
Total Debt To Capitalization3.0E-43.0E-40.0024
Slightly volatile
Debt Equity Ratio3.0E-43.0E-40.0024
Slightly volatile
Quick Ratio9.177.87658.1294
Pretty Stable
Net Income Per E B T1.11.151.0148
Slightly volatile
Cash Ratio8.045.71186.4486
Slightly volatile
Days Of Sales Outstanding39437695.4517
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.00170.9888
Slightly volatile
Price To Book Ratio6.175.8722.2482
Slightly volatile
Fixed Asset Turnover37.6439.618527
Slightly volatile
Debt Ratio2.0E-43.0E-40.002
Slightly volatile
Price Sales Ratio18717830.0067
Slightly volatile
Asset Turnover0.02780.02930.173
Slightly volatile
Gross Profit Margin0.80.90.98
Slightly volatile
Price Fair Value6.175.8722.2482
Slightly volatile

NewAmsterdam Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.2 B4 B927.3 M
Slightly volatile

NewAmsterdam Fundamental Market Drivers

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4 M5.7 M
Total Revenue22.5 M33.9 M
Cost Of Revenue59 K66.4 K
Stock Based Compensation To Revenue 2.64  2.77 
Sales General And Administrative To Revenue 4.72  4.96 
Research And Ddevelopement To Revenue 6.30  4.36 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.20  0.19 
Ebit Per Revenue(10.03)(10.53)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY